Sign in
4

Changes in Ownership

TEVA PHARMACEUTICAL INDUSTRIES LTD Filed Acc 0001209191-19-016085

Executive VP, Global R&D sold 409 shares at $16.88 ($6,905)

  • Executive VP, Global R&D acquired 1,165 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Fridriksdottir Hafrun · Executive VP, Global R&D

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2019-03-04 Exercise or conversion : show line 1 in the form +1,165 16,502.51 D
2019-03-04 Sale : show line 2 in the form −409 $16.88 $6,905 16,093.51 D
Open-market sales · 409 sh · avg $16.88 · $6,905

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2019-03-04 Exercise or conversion : show line 3 in the form Restricted Share Units −1,165 0 D
Loading xslF345X03/doc4.xml…